(NASDAQ: ACLX) Arcellx's forecast annual revenue growth rate of 54.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.57%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.38%.
Arcellx's revenue in 2025 is $76,809,000.On average, 5 Wall Street analysts forecast ACLX's revenue for 2025 to be $4,075,636,647, with the lowest ACLX revenue forecast at $1,790,967,848, and the highest ACLX revenue forecast at $7,880,258,529. On average, 5 Wall Street analysts forecast ACLX's revenue for 2026 to be $9,826,847,706, with the lowest ACLX revenue forecast at $5,466,584,938, and the highest ACLX revenue forecast at $15,836,233,668.
In 2027, ACLX is forecast to generate $15,517,276,071 in revenue, with the lowest revenue forecast at $12,503,710,911 and the highest revenue forecast at $17,926,210,486.